BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28631135)

  • 21. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.
    Remon J; Isla D; Garrido P; de Castro J; Majem M; Viñolas N; Artal A; Carcereny E; García-Campelo MR; Lianes P; Provencio M; Juan O; Diz P; Blanco R; Lopez-Castro R; Maestu I; Vadell C; Felip E
    Clin Transl Oncol; 2017 Dec; 19(12):1537-1542. PubMed ID: 28660482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.
    Aydiner A; Yildiz I; Seyidova A
    Asian Pac J Cancer Prev; 2013; 14(5):3255-61. PubMed ID: 23803112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
    Fiala O; Pesek M; Finek J; Krejci J; Ricar J; Bortlicek Z; Benesova L; Minarik M
    Neoplasma; 2013; 60(1):26-32. PubMed ID: 23067213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
    Komaki R; Allen PK; Wei X; Blumenschein GR; Tang X; Lee JJ; Welsh JW; Wistuba II; Liu DD; Hong WK
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):317-24. PubMed ID: 25968826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
    Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP
    J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].
    Duan JC; An TT; Wu MN; Yang L; Bai H; Wang ZJ; Wang YY; Zhuo ML; Zhao J; Wang SH; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 May; 35(5):323-8. PubMed ID: 22883988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
    He C; Liu M; Zhou C; Zhang J; Ouyang M; Zhong N; Xu J
    Int J Cancer; 2009 Nov; 125(10):2393-9. PubMed ID: 19530244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    Kaneda T; Yoshioka H; Tamiya M; Tamiya A; Hata A; Okada A; Niwa T; Shiroyama T; Kanazu M; Ishida T; Katakami N
    BMC Cancer; 2018 Jan; 18(1):6. PubMed ID: 29291705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation].
    Wang ZH; Song XY
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):90-93. PubMed ID: 28219201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
    Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
    Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
    Takeda M; Okamoto I; Fujita Y; Arao T; Ito H; Fukuoka M; Nishio K; Nakagawa K
    J Thorac Oncol; 2010 Mar; 5(3):399-400. PubMed ID: 20186026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
    Cho SH; Park LC; Ji JH; Park S; Hwang DW; Lee JY; Choi YL; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):315-20. PubMed ID: 22760226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
    Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
    BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
    Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
    J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors.
    Barnet MB; O'Toole S; Horvath LG; Selinger C; Yu B; Ng CC; Boyer M; Cooper WA; Kao S
    J Thorac Oncol; 2017 Mar; 12(3):585-590. PubMed ID: 27639677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.